Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older

Background Because SARS-CoV-2 mutations and immunity wane over time, a third dose of heterologous COVID-19 vaccine is proposed for individuals primed with inactivated COVID-19 vaccine. Research design and methods We conducted a single-center, open-label trial to assess the safety, immunogenicity, an...

Full description

Bibliographic Details
Main Authors: Yingping Chen, Xinpei Zhang, Lihui Gong, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Yuting Liao, Lingfeng Yuan, Gang Chen, Huakun Lv
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Expert Review of Vaccines
Subjects:
covid-19
heterologous booster
immune-persistence
immunogenicity
safety
Online Access:http://dx.doi.org/10.1080/14760584.2023.2274491

Internet

http://dx.doi.org/10.1080/14760584.2023.2274491

Similar Items